Kura Oncology Inc. (KURA)

NASDAQ: KURA · Real-Time Price · USD

6.48

-0.08 (-1.22%)

At close: May 01, 2025, 3:59 PM

6.41

-1.16%

After-hours: May 01, 2025, 05:46 PM EDT

-1.22% (1D)

Bid	5.75
Market Cap	523.44M
Revenue (ttm)	53.88M
Net Income (ttm)	-173.98M
EPS (ttm)	-2.02
PE Ratio (ttm)	-3.21
Forward PE	-3.54
Analyst	Buy

Ask	6.7
Volume	1,095,087
Avg. Volume (20D)	1,472,786
Open	6.52
Previous Close	6.56
Day's Range	6.36 - 6.55
52-Week Range	5.41 - 23.48
Beta	0.82

About KURA

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, includi...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 16, 2015

Employees 192

Stock Exchange NASDAQ

Ticker Symbol KURA

Website https://kuraoncology.com

Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for KURA stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 332.10% from the latest price.

Stock Forecasts

Earnings Surprise

New

Kura Oncology has released their quartely earnings on May 1, 2025:

Revenue of $14.11M misses estimates by $24.97M, with Infinity% YoY growth.

EPS of -0.66 misses estimates by -0.06, with -11.86% YoY decline.

Why Price Moved

2 months ago

-2.54%

Kura Oncology shares are trading lower. The compan... Unlock content with Pro Subscription

2 months ago

+1.8%

Kura Oncology shares are trading lower. The company announced topline results from KOMET-001.

News

22 hours ago · seekingalpha.com

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Troy Wilson – President and Chief Executive Officer Mollie Leoni – Chief Medical Officer...

1 day ago · zacks.com

Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates

Kura Oncology (KURA) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.59 per share a year ago.

1 month ago · seekingalpha.com

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations throu...

2 months ago · seekingalpha.com

Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript

Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank - IR Troy Wilson - President and CEO Mollie Leoni - CMO Tom Doyle - SVP...

2 months ago · zacks.com

Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates

Kura Oncology (KURA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.55 per share a year ago.

2 months ago · benzinga.com

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

Kura Oncology, Inc. KURA and Kyowa Kirin Co., Ltd released topline results from a Phase 2 registration-directed trial of ziftomenib for relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leu...